French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and Medidata, a Dassault Systèmes (Euronext Paris:DSY) brand, on Thursday announced an expansion of their more than 10-year collaboration to enhance clinical research.
The partnership will leverage Medidata Experiences across patient, data, and study workflows to streamline operations, improve data quality, and advance patient care.
The platform-based solutions integrate AI into clinical trial processes, reducing fragmentation, lowering costs, and accelerating timelines.
Sanofi will utilise Medidata's expertise in decentralised clinical trials as part of the agreement. Medidata will provide strategic consulting and end-to-end operational support, enabling Sanofi to optimise research processes and enhance the precision and impact of therapy development.
Myosin Therapeutics' MT-125 granted US FDA Fast Track designation in glioblastoma
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio